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SUMMARY. Esophageal cancer is one of the most common cancer killers in our country. The effects of
racial disparities on care for esophageal cancer patients are incompletely understood. Using the National Cancer
Database, we investigated racial disparities in treatment and outcome of esophageal cancer patients. The National
Cancer Database was queried from 2004 to 2017. Logistic regression and survival analysis were used to determine
racial differences in access, treatment and outcome. A total of 127,098 patients were included. All minority groups
were more likely to be diagnosed at advanced stages versus Caucasians after adjusting for covariates (African
American OR—1.64 [95% confidence interval 1.53—1.76], Hispanic OR—1.19 [1.08—1.32], Asian OR—1.78
[1.55—2.06]). After adjustment, all minorities were less likely at every stage to receive surgery. Despite these
disparities, Hispanics and Asians had improved survival compared with Caucasians. African Americans had worse
survival. Racial disparities for receiving surgery were present in both academic and community institutions, and
at high-volume and low-volume institutions. Surgery partially mediated the survival difference between African
Americans and Caucasians (HR—1.13 [1.10–1.16] and HR—1.04 [1.02–1.07], without and with adjustment of
surgery).There are racial disparities in the treatment of esophageal cancer. Despite these disparities, Hispanics and
Asians have improved overall survival versus Caucasians. African Americans have the worst overall survival. Racial
disparities likely affect outcome in esophageal cancer. But other factors, such as epigenetics and tumor biology,
may correlate more strongly with outcome for patients with esophageal cancer.
KEY WORDS: cancer epidemiology, cancer treatment, esophageal cancer.

INTRODUCTION
Esophageal cancer is one of the leading causes of
cancer-related deaths in the USA. Over 17,000 people in the USA die each year from esophageal cancer.1 Despite advances in surgical management and
chemoradiation protocols, the 5 year survival rate of
esophageal cancer is still only 17%.2
Recent tragedies in this country have displayed the
crisis of systemic injustice and lack of equity in our
society.3 Racial disparities exist in many systems in
our country, including the health care system. Only
4% of all physicians in this country are African American.4 Hispanic patients are frequently underrepresented as participants in clinical trials.5 And many

treatment protocols are based on investigative studies
which did not include patients of Asian descent.6
Minorities diagnosed with several different cancer types have been shown to have worse outcomes
than Caucasians7–9 . But some minority groups have
traditionally experienced less complications in some
disease processes compared with the rest of the population.10 Although such studies have been performed
for esophageal cancer, the literature has been limited
in determining causes or correlations to explain these
disparities in care. As such, our goals were to determine the racial disparities in access to care, treatment
and outcomes in patients diagnosed with esophageal
cancer. The National Cancer Database (NCDB) was
queried over a 14 year period to perform this analysis.
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Disparities in esophageal cancer care based on race: a National Cancer Database
analysis
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METHODS
Patients

Variables

The following variables were collected for each
patient: age, gender, ethnicity, medical insurance
status, level of education, income level, CharlsonDeyo comorbidity score, distance from the patient’s
residence to the treating institution, urban versus
rural location of patient residence, year of diagnosis,
T category, N category, M category, clinical stage,
pathologic stage, type of treating institution, highvolume versus low-volume esophagectomy institution, type of treatment given (surgery, chemotherapy,
radiation), time from diagnosis to start of treatment
and to mortality. A center was considered to be highvolume if it performed more than an average of 13
or more esophagectomies per year, as 13 was the
guideline by the Leapfrog Group during the midpoint
of the study.12 A patient was said to have received ‘any
treatment’ if they received surgery, chemotherapy or
radiation individually or as multimodality treatment.
Carcinoma in situ was considered Stage 0. Stages III
and IV were considered to be advanced stage.
Statistical methods

Demographic, cancer characteristics, facility characteristics and treatments by race/ethnicity (Caucasian,
Africa Americans, Hispanic, Asians and others) were
presented as means, standard deviation, median and
quartile 1 and 3 for continuous variables, and as
frequencies and percentage for categorical variables.
A logistic regression model was used to compare
the race/ethnicity disparity on stage of diagnosis
adjusted for demographics and facility characteristics.
We also built stratified logistic regression models by

Fig. 1 CONSORT diagram of patients.

stage to assess the race/ethnicity disparity on various
treatments with the same adjustments. Interactions
between race/ethnicity and facility characteristics on
the outcomes of treatment were tested. To examine
the race/ethnicity disparity on survival, unadjusted
survival rates were estimated by using Kaplan–
Meier method and compared with the log-rank
test. Multivariate Cox Proportional Hazard models
were used to estimate hazard ratios adjusted for
demographics and facility characteristics. To assess
the effect of stage at diagnosis and treatments on
race/ethnicity disparity of survival, we added these
variables step by step to the Cox proportional hazard
model. All patients were censored at the last contact
date or at the end of study (December 31, 2019). The
proportional hazard assumption was evaluated first
by visual inspection of the Kaplan–Meier curve and
then by adding the interaction between race and log
(time) to the model and checking for significance.
In both the Kaplan–Meier analysis and the Cox
proportional hazards model, patients diagnosed in
2017 were excluded due to not having follow-up
information. All analyses were conducted using SAS
9.4 (Cary, NC).
RESULTS
Demographics

A total of 169,893 patients were available in the
database for review. After exclusion of patients with
missing data and those that did not fit criteria,
127,098 patients were included in the analysis (Fig. 1).
Table 1 lists patient demographics. The age of
African American patients (63.7 ± 10.4 years) and
Hispanic patients (64.9 ± 11.5 years) tended to
lower than Caucasian patients (66.9 ± 10.9 years)
and Asian patients (66.9 ± 11.0 years). The highest
proportion of female patients was among African
Americans (31.8%), followed by Asians (24.9%),
Hispanics (20.0%) and Caucasians (19.7%). Distance
from the treating institution was lowest for African
Americans (16.2 ± 64.4 miles), followed by Hispanics
(22.7 ± 82.9 miles), Asians (24.0 ± 160.1 miles) and
Caucasians (34.2 ± 109.3 miles). The highest per-

Downloaded from https://academic.oup.com/dote/advance-article/doi/10.1093/dote/doab083/6464405 by Henry Ford Hospital user on 15 February 2022

The NCDB was developed as a joint project of the
Commission on Cancer of the American College of
Surgeons and the American Cancer Society as a comprehensive database of cancer cases in the USA.11 The
NCDB is a clinical oncology database which acquires
hospital registry data from over 15,000 Commission
on Cancer-accredited facilities. The NCDB contains
over 70% of all newly diagnosed cancer cases and has
more than 34 million records overall. The NCDB was
queried for all cases of esophageal cancer from 2004
to 2017. Only patients who had the esophagus as the
primary site of their cancer were included. Patients
who had overlapping primary sites were excluded.
The data used in the study were derived from a deidentified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn
from these data by the investigators.
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Table 1 Patient demographics

African American Hispanic
(N = 11,605)
(N = 4241)

Asian
(N = 2041)

Othe
r (N = 1955)

66.9 ± 10.9
67 (59–75)
6125 (5.7%)
22,114 (20.6%)
34,704 (32.4%)
29,088 (27.1%)
15,225 (14.2%)

63.7 ± 10.4
63 (56–71)
938 (8.1%)
3378 (29.1%)
3973 (34.2%)
2442 (21.0%)
874 (7.5%)

64.9 ± 11.5
65 (56–73)
415 (9.8%)
1036 (24.4%)
1297 (30.6%)
976 (23.0%)
517 (12.2%)

66.9 ± 11.0
67 (59–75)
130 (6.4%)
400 (19.6%)
653 (32.0%)
592 (29.0%)
266 (13.0%)

65.8 ± 10.9
66 (58–74)
130 (6.7%)
445 (22.8%)
634 (32.4%)
516 (26.4%)
230 (11.8%)

86,145 (80.3%)
21,111 (19.7%)

7916 (68.2%)
3689 (31.8%)

3393 (80.0%)
848 (20.0%)

1533 (75.1%)
508 (24.9%)

1520 (77.8%)
435 (22.3%)

86,437 (80.6%)
18,570 (17.3%)
2249 (2.1%)

10,146 (87.4%)
1299 (11.2%)
160 (1.4%)

3983 (93.9%)
241 (5.7%)
17 (0.4%)

1986 (97.3%)
53 (2.6%)
2 (0.1%)

1575 (80.6%)
321 (16.4%)
59 (3.0%)

2734 (2.6%)
38,100 (35.5%)
5485 (5.1%)
58,858 (54.9%)
2079 (1.9%)

943 (8.1%)
2660 (22.9%)
2485 (21.4%)
5285 (42.5%)
232 (2.0%)

377 (8.9%)
1301 (30.7%)
641 (15.1%)
1871 (44.1%)
51 (1.2%)

134 (6.6%)
703 (34.4%)
327 (16.0%)
865 (42.4%)
12 (0.6%)

69 (3.5%)
677 (34.6%)
182 (9.3%)
912 (46.7%)
115 (5.9%)

14,165 (13.2%)
25,122 (23.4%)
30,798 (28.7%)
37,171 (34.7%)

5716 (49.3%)
2488 (21.4%)
1991 (17.2%)
1410 (12.2%)

1154 (27.2%)
949 (22.4%)
1095 (25.8%)
1043 (24.6%)

152 (7.5%)
322 (15.8%)
505 (24.7%)
1062 (52.0%)

345 (17.7%)
387 (19.8%)
505 (25.8%)
718 (36.7%)

76,252 (71.1%)
21,801 (20.3%)
6217 (5.8%)
2986 (2.8%)

8278 (71.3%)
2261 (19.5%)
686 (5.9%)
380 (3.3%)

3068 (72.3%)
821 (19.4%)
214 (5.1%)
138 (3.3%)

1580 (77.4%)
369 (18.1%)
63 (3.1%)
29 (1.4%)

1426 (72.9%)
366 (18.7%)
110 (5.6%)
53 (2.7%)

32,013 (29.9%)
25,786 (24.0%)
33,908 (31.6%)
15,549 (14.5%)

2423 (20.9%)
2094 (18.0%)
6603 (56.9%)
485

409 (9.6%)
1006 (23.7%)
1471 (34.7%)
1355 (32.0%)

209 (10.2%)
558 (27.3%)
328 (16.1%)
946 (46.4%)

478 (24.5%)
496 (25.4%)
467 (23.9%)
514 (26.3%)

34.2 ± 109.3
11.8 (4.9–29.4)

16.2 ± 64.4
5.9 (2.7–14.0)

22.7 ± 82.9
7.0 (3.2–15.3)

24.0 ± 160.1
6.3 (3.0–12.1)

66.3 ± 211.4
15.0 (5.2–49.8)

9830 (9.2%)
42,390 (39.5%)
41,803 (39.0%)
13,233 (12.3%)

850 (7.3%)
3777 (32.6%)
5607 (48.3%)
1371 (11.8%)

323 (7.6%)
1370 (32.3%)
2029 (47.8%)
519 (12.2%)

182 (8.9%)
590 (28.9%)
1082 (53.0%)
187 (9.2%)

109 (5.6%)
492 (25.2%)
1116 (57.1%)
238 (12.2%)

60,840 (56.7%)
46,416 (43.3%)

7085 (61.1%)
4520 (39.0%)

2660 (62.7%)
1581 (37.3%)

1097 (53.8%)
944 (46.3%)

783 (40.1%)
1172 (60.0%)

21,560 (20.1%)
22,989 (21.4%)
26,534 (24.7%)
36,173 (33.7%)

1,563 (13.5%)
2402 (20.7%)
3351 (28.9%)
4289 (37.0%)

710 (16.7%)
860 (20.3%)
1104 (26.0%)
1567 (37.0%)

302 (14.8%)
441 (21.6%)
690 (33.8%)
608 (29.8%)

428 (21.9%)
395 (20.2%)
515 (26.3%)
617 (31.6%)

18,098 (16.9%)
89,158 (83.1%)
36.9 ± 34.1

2475 (21.3%)
9130 (78.7%)
39.8 ± 39.4

1019 (24.0%)
3222 (76.0%)
40.9 ± 37.2

422 (20.7%)
1619 (79.3%)
37.4 ± 36.6

450 (23.0%)
1505 (77.0%)
38.9 ± 36.0

32 (19–47)

32 (18–51)

33 (18–53)

31 (18–47)

31 (18–50)

46,145 (43.0%)
61,111 (57.0%)

4483 (38.6%)
7122 (61.4%)

2068 (48.8%)
2173 (51.2%)

794 (38.9%)
1247 (61.1%)

1017 (52.0%)
938 (48.0%)

69,462 (64.8%)
37,794 (35.2%)

9711 (83.7%)
1894 (16.3%)

3078 (72.6%)
1163 (27.4%)

1512 (74.1%)
529 (26.0%)

1300 (66.5%)
655 (33.5%)

40,230 (37.5%)
67,026 (62.5)

4596 (39.6%)
7009 (60.4%)

1794 (42.3%)
2447 (57.7%)

785 (38.5%)
1256 (61.5%)

953 (48.8%)
1002 (51.2%)
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Age at diagnosis
Mean ± SD (years)
Median, 25th–75th percentile (years)
<50
50–59
60–69
70–79
80+
Gender
Male
Female
Urban/Rural
Metro
Urban, non-metro
Rural
Primary Payor
Not insured
Private
Medicaid
Medicare
Other Gov
Income
Q1
Q2
Q3
Q4
Charlson-Deyo Score
0
1
2
3+
Region
Midwest
Northeast
South
West
Distance from patient address to hospital
Mean ± SD (miles)
Median, 25th–75th percentile (miles)
Facility type
Community Cancer Program
Comprehensive Community Cancer Program
Academic/Research
Integrated Network Cancer Program
Facility Volume
<13 per year
13 or greater per year
Overall Stage
0/1
2
3
4
Had Treatment
No
Yes
Time from diagnosis to treatment, mean ± SD
(days)
Time from diagnosis to treatment, median,
25th –75th percentile (days)
Radiation
No
Yes
Surgery
No
Yes
Chemotherapy
No
Yes

White
(N = 107,256)
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Table 2 Odds of being diagnosed at an advanced stage versus Stage 0/1 for each race

Stage 3 versus Stage 0/1

Stage 4 versus Stage 0/1

P-value

Reference
1.43 (1.33–1.54)
1.16 (1.04–1.29)
1.42 (1.22–1.65)

Reference
1.62 (1.51–1.74)
1.18 (1.07–1.31)
1.79 (1.55–2.06)

Reference
1.52 (1.42–1.63)
1.21 (1.09–1.33)
1.20 (1.03–1.39)

Reference
<0.01
<0.01
<0.01

centage of patients in the lowest economic quartile
was among African Americans (49.3%), followed by
Hispanics (27.2%), Caucasians (13.2%) and Asians
(7.5%).
The groups most likely to be treated at academic/research institutions were Asians (53.0%),
followed by African Americans (48.3%), Hispanics
(47.8%) and Caucasians (39.0%). Asians were the
group most likely to be treated at high-volume centers
(46.3%), followed by Caucasians (43.3%), African
Americans (39.0%) and Asians (37.3%).

Table 3 Survival hazard ratios after adjustment for stage and stage
+ surgery

Stage at diagnosis

Overall survival

All minorities were more likely to be diagnosed at
advanced stages compared with Caucasians (Table 2).
The distribution of Stage 0/1, 2, 3 and 4 disease
for African Americans was 13.5%, 20.7%, 28.9%
and 37.0%. The distribution of Stage 0/1, 2, 3 and
4 disease for Hispanics was 16.7%, 20.3%, 26.0%
and 37.0%. The distribution of Stage 0/1, 2, 3 and
4 disease for Asians was 14.8%, 21.6%, 33.8% and
29.8%. The distribution of Stage 0/1, 2, 3 and 4 disease
for Caucasians was 20.1%, 21.4%, 24.7% and 33.7%.
Even when adjusted for other demographics and
facility characteristics, all minorities had significantly
increased odds of being diagnosed at Stages 2, 3 and
4 compared with Caucasians (Table 2).

After adjusting for survival and treatment pattern,
African Americans had a statistically significant
decrease in survival compared with Caucasians
(hazard ratio 1.04, 1.02–1.07) and overall had the
worst survival. In comparison, Hispanics (hazard
ratio 0.82, 0.79–0.85) and Asians (hazard ratio 0.78,
0.74–0.83) had statistically significant improvements
in survival after adjusting for stage and treatment
pattern (Fig. 3). When adjusting only for stage,
African Americans still had an overall worse survival
versus Caucasians (hazard ratio 1.13, 1.10–1.15,
Table 3).

Treatment pattern

The likelihood of receiving surgery is shown in
Figure 2 for every race at every stage. Minorities
tended to be less likely to receive surgery at every
stage compared with Caucasians. For Stage 0/1, 2, 3
and 4 disease, African Americans had hazard ratios
of 0.34, 0.39, 0.33 and 0.46, respectively, of receiving
surgery compared with Caucasians. For Stage 0/1, 2,
3 and 4 disease, Hispanics had hazard ratios of 0.72,
0.90, 0.63 and 0.99, respectively, of receiving surgery
compared with Caucasians. For Stage 0/1, 2, 3 and 4
disease, Asians had hazard ratios of 0.46, 0.72, 0.49
and 1.02, respectively, of receiving surgery compared
with Caucasians. In particular, African Americans
were the least likely to be offered surgery. Only 16.3%
of African Americans received surgery, compared
with 33.1% of the overall cohort.

Ethnicity

Hazard ratio
adjusted for stage

Hazard ratio
adjusted for stage
and surgery

Caucasian
African American
Hispanic
Asian
Other

Reference
1.13 (1.10–1.15)
0.84 (0.81–0.88)
0.83 (0.78–0.87)
0.96 (0.91–1.01)

Reference
1.04 (1.02–1.07)
0.82 (0.79–0.85)
0.78 (0.74–0.83)
0.93 (0.88–0.98)

DISCUSSION
Our study revealed that there were racial disparities in treatment pattern and outcome for patients
with esophageal cancer. Minorities tended to be diagnosed at advanced stages. This trend has been seen in
numerous other disease processes13–15 . There are multiple potential reasons for this disparity, and opportunities to reduce these inequities. Firstly, screening
rates for many cancers are lower in minorities16,17 .
Patients eligible for screening for esophageal cancer include men or women with chronic symptoms
(greater than 5 years) of gastroesophageal reflux disease (GERD) and two or more risk factors for Barrett’s esophagus or esophageal adenocarcinoma. Risk
factors included Caucasian race, age ≥50 years, current or prior history of smoking, central obesity as
defined as a waist circumference greater than 88 cm,
waist to hip ratio greater than 0.8 or a family history of Barrett’s esophagus or esophageal adenocarci-
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Caucasian
African American
Hispanic
Asian

Stage 2 versus 0/1
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noma.18 A focused intervention improving awareness
of the benefits of screening in minority communities
would help to diagnose disease earlier. This awareness
campaign can target both the community and health
care providers in these areas. Although the medical
community strives to treat all patients equally, cultural
stereotypes and unconscious biases may contribute to
health disparities.19 These awareness campaigns will
require counseling of providers as well as patients to
be effective.
Secondly, there were treatment disparities based on
race that were evident in our study. African Americans were less likely to receive surgery at all stages.
Although tumor biology likely affected outcome, the
disparity in receiving surgery affected outcome as
well. Other studies have shown that African Americans are less likely to receive surgery for several disease
processes, and that when African Americans receive
surgery the disease process is more advanced.20 There
are multiple reasons for this disparity in receiving
surgery. Unfortunately, there are large segments of the
African American population which are hesitant to
seek medical care and have suspicion of the medical
community21,22 . In addition, previous literature has
shown that providers are less likely to offer surgery to

minorities when indicated.23 Educating providers and
patients about all treatment options is likely to reduce
this disparity in receiving surgery.
An interesting finding in our study was that Hispanic and Asian patients had a better survival overall, despite disparities in care. Our study is novel in
that we showed that for some disease processes like
esophageal cancer, the biology of the disease may be
more critical than the access to treatment. Esophageal
cancer is associated with a very poor prognosis compared with other solid organ tumors. The tumor biology and epigenetic factors of esophageal cancer may
impact outcome, but future studies are required to
examine this correlation.
This trend has been described previously in
Hispanic patients as the ‘Hispanic paradox’ phenomenon24,25 . Multiple genes have been identified
which are related to esophageal cancer development
and are differentially expressed in various races.
Further research may identify that some of these
differentially expressed genes are related to racial
differences in outcome.
Our study defined ‘high-volume’ based on the
number of yearly esophagectomies determined by
The Leapfrog Group. Multiple studies have shown
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Fig. 2 Odds of treatments being given based on race after adjustment for covariates. African Americans and Hispanics had lower odds of
any treatment being given at all stages.
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that as a center performs more surgeries, their
outcomes improve. But previous studies have not
examined whether high-volume centers provide more
equitable care than low-volume centers. Our study
showed that the disparities in treatment patterns
were present at both high-volume and low-volume
institutions. Despite having more familiarity with
esophagectomies, high-volume centers still offered
surgery less frequently to minorities. Similarly, disparities in treatment were present at academic/research
and community institutions. This disparity exists
for reasons other than familiarity with esophageal
cancer, and a solution will have to target all types of
institutions to be effective.
Analysis of disparities in treatment pattern can
possibly be complicated by interactions of social
determinants with each other26,27 . Minorities are
more likely to be in lower income levels and are
more likely to be uninsured.28 We attempted logistic
regression analysis to determine the impact of
individual factors on treatment pattern and outcome,
but there are likely relationships between some social
determinants which are not fully measured in the
database.

There were several limitations to our study.
Although the NCDB is quite robust, there were no
cancer-specific survival data available. Secondly, the
information on chemotherapy and radiation lacked
details such as dose and regimen used. Thirdly, some
sociodemographic information such as income and
education levels was measured at the zip code level
and not for each individual. Fourthly, although the
overall stage was present in most cases, the specific
TNM categories were missing in many situations.
Additionally, complete histologic data were not
available and could have had some impact on the
interpretation of the data. Despite these limitations,
the vast amount of data and large number of patients
made this study useful and revealing.
Esophageal cancer is a morbid disease with a relatively low 5 year survival. There are significant disparities in treatment patterns in this country based
on race. Despite these disparities, Hispanic and Asian
patients have better outcomes. As such, it appears
that tumor biology and epigenetic phenomena impact
outcome meaningfully in esophageal cancer. Future
efforts to reduce treatment disparities should focus
on patients and providers. In addition, future research
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Fig. 3 Survival by race.

Disparities in esophageal cancer care

should search for race-related differential gene expression which may explain differences in outcome related
to race.
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